Veracyte Company Profile (NASDAQ:VCYT)

About Veracyte (NASDAQ:VCYT)

Veracyte logoVeracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VCYT
  • CUSIP: N/A
  • Web:
  • Market Cap: $276.38 million
  • Outstanding Shares: 33,870,000
Average Prices:
  • 50 Day Moving Avg: $8.30
  • 200 Day Moving Avg: $7.95
  • 52 Week Range: $4.81 - $9.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $67.97 million
  • Price / Sales: 4.07
  • Book Value: $1.58 per share
  • Price / Book: 5.16
  • EBIDTA: ($23,990,000.00)
  • Net Margins: -57.45%
  • Return on Equity: -88.36%
  • Return on Assets: -46.01%
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 4.18%
  • Quick Ratio: 3.85%
  • Average Volume: 144,779 shs.
  • Beta: 2
  • Short Ratio: 1.44

Frequently Asked Questions for Veracyte (NASDAQ:VCYT)

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.24) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.24). The company had revenue of $16.43 million for the quarter, compared to the consensus estimate of $18.09 million. Veracyte had a negative return on equity of 88.36% and a negative net margin of 57.45%. View Veracyte's Earnings History.

When will Veracyte make its next earnings announcement?

Veracyte is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Veracyte.

Where is Veracyte's stock going? Where will Veracyte's stock price be in 2017?

6 analysts have issued 12-month price targets for Veracyte's shares. Their predictions range from $10.00 to $13.00. On average, they anticipate Veracyte's share price to reach $11.75 in the next twelve months. View Analyst Ratings for Veracyte.

What are analysts saying about Veracyte stock?

Here are some recent quotes from research analysts about Veracyte stock:

  • 1. According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (3/7/2017)
  • 2. Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)

Who are some of Veracyte's key competitors?

Who owns Veracyte stock?

Veracyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include TPG Group Holdings SBS Advisors Inc. (10.49%), Eventide Asset Management LLC (6.30%), Broadfin Capital LLC (4.87%), Cannell Capital LLC (4.73%), Vanguard Group Inc. (2.44%) and Stonepine Capital Management LLC (1.71%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Jesse I Treu and Shelly D Guyer. View Institutional Ownership Trends for Veracyte.

Who sold Veracyte stock? Who is selling Veracyte stock?

Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Grandeur Peak Global Advisors LLC, Broadfin Capital LLC, Eventide Asset Management LLC, Axiom International Investors LLC DE, Oxford Asset Management, Morgan Stanley and Goldman Sachs Group Inc.. Company insiders that have sold Veracyte stock in the last year include Bonnie H Anderson and Jesse I Treu. View Insider Buying and Selling for Veracyte.

Who bought Veracyte stock? Who is buying Veracyte stock?

Veracyte's stock was purchased by a variety of institutional investors in the last quarter, including Cannell Capital LLC, Cortina Asset Management LLC, Renaissance Technologies LLC, TFS Capital LLC, EAM Investors LLC, Boston Advisors LLC, Vanguard Group Inc. and Trexquant Investment LP. View Insider Buying and Selling for Veracyte.

How do I buy Veracyte stock?

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Veracyte stock cost?

One share of Veracyte stock can currently be purchased for approximately $8.16.

Analyst Ratings

Consensus Ratings for Veracyte (NASDAQ:VCYT) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.75 (44.00% upside)

Analysts' Ratings History for Veracyte (NASDAQ:VCYT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
3/10/2017BTIG ResearchReiterated RatingBuy$12.00N/AView Rating Details
11/29/2016Janney Montgomery ScottUpgradeNeutral -> BuyN/AView Rating Details
11/22/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
10/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$12.00 -> $10.00N/AView Rating Details
11/19/2015StephensReiterated RatingBuyN/AView Rating Details
10/14/2015Cowen and CompanyLower Price TargetOutperform$12.00 -> $8.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for Veracyte (NASDAQ:VCYT)
Earnings by Quarter for Veracyte (NASDAQ:VCYT)
Earnings History by Quarter for Veracyte (NASDAQ:VCYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.24)($0.24)$18.09 million$16.43 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.14)$17.49 million$18.30 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Veracyte (NASDAQ:VCYT)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20172($0.27)($0.26)($0.27)
Q3 20171($0.23)($0.23)($0.23)
Q4 20172($0.22)($0.22)($0.22)
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.17)($0.17)($0.17)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)


Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Veracyte (NASDAQ:VCYT)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 47.50%
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Jesse I TreuDirectorSell2,226$8.08$17,986.08View SEC Filing  
3/21/2017Bonnie H AndersonChairmanSell5,000$9.09$45,450.00View SEC Filing  
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Veracyte (NASDAQ:VCYT)
Latest Headlines for Veracyte (NASDAQ:VCYT)
DateHeadline logoVeracyte Inc (VCYT) Receives Average Recommendation of "Buy" from Analysts - May 22 at 7:44 AM logoVeracyte (VCYT) Reports Anthem Coverage for Afirma GEC for Use in Thyroid Cancer Diagnosis - May 19 at 11:39 PM logoCantor Fitzgerald Reiterates "$13.00" Price Target for Veracyte Inc (VCYT) - May 19 at 6:36 PM logoVeracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis - May 19 at 1:35 PM logoVeracyte Inc (VCYT) Director Sells $17,986.08 in Stock - May 18 at 8:33 PM logo$18.27 Million in Sales Expected for Veracyte Inc (VCYT) This Quarter - May 13 at 9:24 AM logoFY2017 EPS Estimates for Veracyte Inc (VCYT) Reduced by Cantor Fitzgerald - May 12 at 11:44 AM logoData Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology" - May 12 at 3:45 AM logoVeracyte Inc (VCYT) Expected to Announce Earnings of -$0.24 Per Share - May 11 at 8:06 AM logoWilliam Blair Brokers Lower Earnings Estimates for Veracyte Inc (VCYT) - May 11 at 7:34 AM logoVeracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017 - May 10 at 9:58 AM logoETFs with exposure to Veracyte, Inc. : May 9, 2017 - May 9 at 8:00 PM logoVeracyte, Inc. :VCYT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017 - May 8 at 8:00 PM logoData Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis - May 8 at 9:12 AM logoQ2 2017 EPS Estimates for Veracyte Inc Cut by Analyst (VCYT) - May 8 at 8:21 AM logoVeracyte Inc (VCYT) Given a $13.00 Price Target at Cantor Fitzgerald - May 7 at 12:28 AM logoVeracyte Announces Pivotal Clinical Validation Data for Next-Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis - May 5 at 3:11 AM logoVeracyte Inc (VCYT) Posts Quarterly Earnings Results, Meets Expectations - May 4 at 10:09 PM logoVeracyte Announces First Quarter 2017 Financial Results - May 3 at 6:49 PM logoVeracyte reports 1Q loss - May 3 at 6:49 PM logoVeracyte (VCYT) Earns Media Sentiment Rating of 0.39 - May 3 at 11:20 AM logoVeracyte Inc (VCYT) to Release Quarterly Earnings on Wednesday - May 1 at 5:02 PM logoVeracyte (VCYT) Getting Somewhat Negative Press Coverage, Study Shows - April 30 at 9:02 AM logoVeracyte (VCYT) Receives News Sentiment Score of 0.34 - April 27 at 12:02 PM logoVeracyte Announces Multiple Studies Demonstrating Powerful Results from Afirma® Classifiers To Be Presented at the AACE 2017 Annual Meeting - April 26 at 8:26 AM logoVeracyte Inc (VCYT) Given Average Rating of "Buy" by Analysts - April 25 at 10:59 AM logoSomewhat Negative News Coverage Extremely Likely to Impact Veracyte (VCYT) Share Price - April 24 at 12:34 PM logoZacks: Analysts Expect Veracyte Inc (VCYT) Will Post Quarterly Sales of $18.09 Million - April 22 at 9:11 AM logoVeracyte (VCYT) Getting Somewhat Favorable Press Coverage, AlphaOne Reports - April 20 at 7:45 PM logo Analysts Anticipate Veracyte Inc (VCYT) to Announce -$0.24 Earnings Per Share - April 20 at 11:15 AM logoVeracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017 - April 19 at 8:50 PM logoVeracyte (VCYT) Earns News Sentiment Score of 0.04 - April 17 at 10:56 AM logoVeracyte Inc (VCYT) Sees Significant Decline in Short Interest - April 13 at 11:28 PM logoMultiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis - April 3 at 8:31 PM logoVeracyte Inc (VCYT) Given Consensus Rating of "Buy" by Brokerages - March 30 at 12:46 PM logoVeracyte (VCYT) Says Multiple Studies Supporting Clinical Utility of Afirma Gene Expression Classifier to Be Presented at ENDO - March 25 at 8:08 PM logoInsider Selling: Veracyte Inc (VCYT) Chairman Sells 5,000 Shares of Stock - March 23 at 7:54 PM logoVeracyte Announces that Multiple Studies Supporting Clinical Utility of Its Afirma® Gene Expression Classifier To Be Presented at ENDO 2017 - March 23 at 3:50 PM logoVERACYTE, INC. Financials - March 7 at 8:42 PM logoVERACYTE, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 6 at 7:49 PM logoVeracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook - March 2 at 1:11 AM logo4:06 pm Veracyte promotes Christopher M. Hall to President and COO - March 1 at 9:03 AM logoQ4 2016 Veracyte Inc Earnings Release - After Market Close - March 1 at 9:03 AM logoVeracyte Announces Executive Promotions - February 28 at 8:08 PM logoVeracyte Announces Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis - February 27 at 5:19 PM logoVeracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis - February 21 at 4:25 PM logoVeracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017 - February 17 at 5:58 AM logoVeracyte (VCYT) Down as Access for Afirma Broadened - February 9 at 6:31 AM logoVeracyte (VCYT) Announces Final Medicare Coverage Policies for Percepta - February 7 at 3:49 PM logoVeracyte Announces Final Medicare Coverage Policies for Percepta® Bronchial Genomic Classifier - February 6 at 10:24 AM


Veracyte (VCYT) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff